Recombinant Anti-CD3 x Anti-CD30 Bispecific Antibody (scDiabody-CH3) (SCDBC-065)

Recombinant Anti-CD3 x Anti-CD30 Bispecific Antibody (scDiabody-CH3) is a fusion protein of two scDiabodies connected together by a CH3 region. In single-chain Diabodies, an additional connecting linker is introduced between chains of the anti-CD3/anti-CD30 diabody. The scDiabody with two specificities is fused to each of the CH3 chains to extend half-life. This BsAb can retarget T cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL) therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & CD30

Type

Constant Domain-extended Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Hodgkin lymphoma; T cell lymphoma; Anaplastic large cell lymphoma (ALCL)

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

CD30

Gene ID

943

UniProt ID

A5D8T4

Alternative Names

CD30; TNFRSF8; tumor necrosis factor receptor superfamily member 8; TNF receptor superfamily member 8; CD30; Ki-1; D1S166E

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-CD30 Bispecific Antibody (scDiabody-CH3) (SCDBC-065). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD3 x Anti-CD30 Bispecific Antibody (scDiabody-CH3) (CAT#: SCDBC-065)

Specifications

Targets

Customer Reviews and Q&As